| Document |
Document Title |
|
WO/2023/220219A1 |
The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
|
|
WO/2023/215494A1 |
Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
|
|
WO/2023/215906A1 |
Provided herein are KRAS G12D proteolysis targeting chimeras (PROTACs), compositions comprising the KRAS G12D PROTACs, and methods of making and using the KRAS G12D PROTACs, e.g., to promote degradation of KRAS G12D and/or treat KRAS G12...
|
|
WO/2023/215802A1 |
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, ...
|
|
WO/2023/213882A1 |
Compounds of formula (I) processes for their production and their use as pharmaceuticals.
|
|
WO/2023/215801A1 |
The present disclosure provides compounds and pharmaceutically acceptable salts thereof, and methods of using the same in the treatment of cancer or for inhibiting cell growth. The compounds and methods have a range of utilities as thera...
|
|
WO/2023/212239A1 |
Described herein are compounds of formula (I) that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes, such a diseas...
|
|
WO/2023/212535A1 |
The present invention provides compounds of the formula (I):, or a pharmaceutically acceptable salt thereof, wherein A, X1, X2, X3, Y, Z, Z1, Z2, R2 and R6 are as defined herein, for use in the treatment of cancer and a method of treatin...
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/212071A1 |
Provided here is a method of treating a cancer in a subject in need thereof, comprising administering to said subject a combination comprising: (i) about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg,...
|
|
WO/2023/210740A1 |
The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
|
|
WO/2023/207944A1 |
The present invention relates to a crystal form of an FGFR4 inhibitor and use thereof. The present invention provides a compound of formula B in crystalline form. The compound of formula B of the present invention has excellent FGFR4 kin...
|
|
WO/2023/208127A1 |
Disclosed are a series of heteroaryl-substituted bicyclic compounds and use thereof, and particularly, disclosed are a compound represented by formula (P), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/210192A1 |
This compound, represented by a general formula, is useful in a light-emitting device. Ar1 is a benzene ring, a naphthalene ring, a phenanthrene ring, or the like; D is a 5H-benzofuro[3,2-c]carbazol-5-yl group, or the like; A is a cyano ...
|
|
WO/2023/207992A1 |
The present invention relates to an indole derivative, an organic electroluminescent element, a display device, and a lighting device. The indole derivative of the present invention has a relatively high triplet level and a high glass tr...
|
|
WO/2023/207911A1 |
Disclosed are a bicyclic heterocyclic compound, a pharmaceutical composition and an application. Specifically, a compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharma...
|
|
WO/2023/205701A1 |
The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
|
|
WO/2023/205653A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/201780A1 |
Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...
|
|
WO/2023/202383A1 |
Disclosed in the present invention are a tetrahydrothienopyridine deuterated derivative, a preparation method therefor, and pharmaceutical use thereof. The derivative can be used for preparing a medicament for the prevention or treatment...
|
|
WO/2023/202531A1 |
The present invention relates to a carbazole derivative, a luminescent material, a luminescent element, a display device, and a lighting device. The carbazole derivative of the present invention has a relatively high triplet energy level...
|
|
WO/2023/274324A9 |
Disclosed in the present invention are a nitrogen-containing heterocyclic compound, and a preparation method therefor, an intermediate thereof, and an application thereof. The present invention provides a nitrogen-containing heterocyclic...
|
|
WO/2023/202501A1 |
A substituted pyridopyrimidinone compound, a composition comprising same, and use thereof. The compound is a compound represented by formula (I) or a tautomer, a stereoisomer, a prodrug, a crystal form, a pharmaceutically acceptable salt...
|
|
WO/2023/205251A1 |
Disclosed are compounds of formula (I) which modulate bromodomains, pharmaceutical compositions containing said compounds and use of said compounds in therapy.
|
|
WO/2023/205463A1 |
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
|
|
WO/2023/203201A1 |
The invention provides a ternary complex of a cucurbituril host, such as CB[8], with a first aryl guest and second aryl guest, wherein the first aryl guest is a group within a biomolecule, such as insulin, and the first and second aryl g...
|
|
WO/2023/205778A1 |
Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
|
|
WO/2023/204308A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has superior orexin type-2 receptor agonist activity.
|
|
WO/2023/199999A1 |
This compound is represented by general formula (1). In general formula (1), CN represents a cyano group, D12 represents a group represented by general formula (1A), and R101-R104 each independently represent a group represented by gener...
|
|
WO/2023/198078A1 |
The present invention provides compounds as KRAS G12D inhibitors. Specifically, the present invention provides compounds having a structure represented by formula (I), or optical isomers, pharmaceutically acceptable salts, prodrugs, deut...
|
|
WO/2023/197934A1 |
The present invention relates to the technical field of pharmaceutical crystals, and relates to a solid salt form of an opioid receptor antagonist conjugate, a crystal form, a preparation method therefor, a composition, and a use. Specif...
|
|
WO/2023/198191A1 |
Disclosed are a six- and six-membered compound, a preparation method, a pharmaceutical composition, and an application. Provided is a six- and six-membered compound as represented by formula (I) or a pharmaceutically acceptable salt ther...
|
|
WO/2023/193759A1 |
Described herein are HPK1inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder associated with HPK1.
|
|
WO/2023/193085A1 |
The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalen...
|
|
WO/2023/195529A1 |
The present invention provides: a compound that exhibits a coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same. The compound is represented by f...
|
|
WO/2023/196307A1 |
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: (I) which inhibit picomavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compo...
|
|
WO/2023/193054A1 |
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or prodrug thereof: Formula (I) in which R4 is 5-membered cycloalkene or 5-membered heteroaryl, each of which is optionally fused to form a ...
|
|
WO/2023/196429A1 |
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibro...
|
|
WO/2023/186060A1 |
Provided herein are novel compounds, for example, compounds having a structure according to Formula III-1 to III-12, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods o...
|
|
WO/2023/192817A1 |
Provided herein are compounds of Formula (I). Methods for the preparation of the compounds of Formula (I) and intermediates useful in the preparation of the compounds of Formula (I) are described herein. The compounds of Formula (I) may ...
|
|
WO/2023/186069A1 |
A bifunctional chimeric heterocyclic compound of interleukin-1 receptor-associated kinase 4 (IRAK4) represented by formula (I), a preparation method therefor, a pharmaceutical composition thereof and use thereof. The compound recruits IR...
|
|
WO/2023/187191A1 |
Compounds of the formula (I) wherein G1, G2, X, R1, R2, R3, and R4 are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compos...
|
|
WO/2023/179196A1 |
Disclosed are a preparation and application of a Wee1 kinase inhibitor, particularly relating to a compound as shown in formula (I) or formula (II) and a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising t...
|
|
WO/2023/179275A1 |
Disclosed in the present invention are a fused ring unit based on a quinoxaline derivative, a small molecule containing same, a polymer, and preparation methods therefor and the use thereof. In the present invention, a new aromatic unit ...
|
|
WO/2023/182530A1 |
Obtained is an excellent anti-CD39 antibody. Provided is an antibody or an antigen-binding fragment that binds to CD39, and contains heavy-chain CDRs 1-3 and light-chain CDRs 1-3 containing a specific amino acid sequence. This antibody m...
|
|
WO/2023/183585A1 |
The present invention provides compounds of the formula: wherein A, B, D1, X, Y, Z, G, R1, R2, and R3a are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptab...
|
|
WO/2023/143486A9 |
The present invention relates to a salt, crystalline form, solvate or hydrate of 6-(ethylamino)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-d
iazabicyclo[3.1.1]heptane-3-yl)pyrazolo[1,5-a]pyridine-3-car
bonitrile, also relates to a pharm...
|
|
WO/2023/177954A1 |
Compositions and methods for treating malignant tumors with a combination of IAP antagonist and TNFα. TNFα is delivered locally via microphages/T cells transduced with viral vectors encoding a tumor targeting molecule, such as a chimer...
|
|
WO/2023/170699A1 |
The present invention describes tricyclic spiro [chromane-2,4-piperidin]-4(3H)-one with 1,3,4-oxadiazolederivatives of general formula X : Wherein, independently for each occurrence: 0 R is H, Br R' is OH or O A is Wherein B1, B2, B3 and...
|
|
WO/2023/168830A1 |
The present invention belongs to the technical field of biomedicine, and specifically relates to an HEMTAC small molecule degradation agent and the use thereof. In the present invention, it is discovered via research that the HEMTAC smal...
|
